Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers

Liver biopsy is currently the only reliable method to establish nonalcoholic fatty liver disease (NAFLD) severity. However, this technique is invasive and occasionally associated with severe complications. Thus, non-invasive diagnostic markers for NAFLD are needed. Former studies have postulated 18 different serum microRNA biomarkers with altered levels in NAFLD patients. In the present study, we have re-examined the predictive value of these serum microRNAs and found that 9 of them (miR-34a, -192, -27b, -122, -22, -21, -197, -30c and -16) associated to NAFLD severity in our independent cohort. Moreover, miR-192, -27b, -22, -197 and -30c appeared specific for NAFLD, when compared with patients with drug-induced liver injury. Preliminary serum RNAseq analysis allowed identifying novel potential miRNA biomarkers for nonalcoholic steatohepatitis (NASH). The classification performance of validated miRNAs (and their ratios) for NASH was better than that reached by AST, whereas for advanced fibrosis prediction miRNAs did not perform better than the FIB-4 algorithm. Cross-validated models combining both clinical and miRNA variables showed enhanced predictivity. In conclusion, the circulating microRNAs validated demonstrate a better diagnostic potential than conventional serum markers to identify NASH patients and could complement and improve current fibrosis prediction algorithms. The research in this field is still open.

[1]  E. Gorospe,et al.  Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. , 2017, Gastroenterology.

[2]  Clinical Implications. , 2017, Hypertension.

[3]  T. Luedde,et al.  Elevated miR‐122 serum levels are an independent marker of liver injury in inflammatory diseases , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[4]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[5]  G. Danan,et al.  RUCAM in Drug and Herb Induced Liver Injury: The Update , 2015, International journal of molecular sciences.

[6]  Changfei Li,et al.  MiR-122 in hepatic function and liver diseases , 2012, Protein & Cell.

[7]  N. Chalasani,et al.  Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. , 2018, Journal of hepatology.

[8]  C. Richart,et al.  miR33a/miR33b* and miR122 as Possible Contributors to Hepatic Lipid Metabolism in Obese Women with Nonalcoholic Fatty Liver Disease , 2016, International journal of molecular sciences.

[9]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[10]  S. Wold,et al.  PLS-regression: a basic tool of chemometrics , 2001 .

[11]  Yoshiyuki Suzuki,et al.  Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan , 2016, Hepatology International.

[12]  Joan Tordjman,et al.  Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients , 2012, Hepatology.

[13]  C. Hammer,et al.  Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis , 2015, PloS one.

[14]  PolyA RT-PCR-based quantification of microRNA by using universal TaqMan probe , 2012, Biotechnology Letters.

[15]  A. Sanyal,et al.  Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis , 2014, Gut.

[16]  J. Castell,et al.  New microRNA Biomarkers for Drug-Induced Steatosis and Their Potential to Predict the Contribution of Drugs to Non-alcoholic Fatty Liver Disease , 2017, Front. Pharmacol..

[17]  Michael W. Pfaffl,et al.  Normalization Strategies for Microrna Profiling Experiments: a 'normal' Way to a Hidden Layer of Complexity? , 2010 .

[18]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[19]  Q. Pan,et al.  Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population , 2016, World journal of gastroenterology.

[20]  Nicola J. Armstrong,et al.  Haemolysis during Sample Preparation Alters microRNA Content of Plasma , 2011, PloS one.

[21]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[22]  Yoshiyuki Suzuki,et al.  Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma , 2016, BMC Gastroenterology.

[23]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[24]  P. Bedossa.  Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease , 2014, Hepatology.

[25]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[26]  Heidi J. Peltier,et al.  Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. , 2008, RNA.

[27]  D. Klinzing,et al.  Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease , 2016, PloS one.

[28]  K. Furu,et al.  Identification of Endogenous Controls for Use in miRNA Quantification in Human Cancer Cell Lines. , 2016, Cancer genomics & proteomics.

[29]  K. Jażdżewski,et al.  Next generation sequencing reveals microRNA isoforms in liver cirrhosis and hepatocellular carcinoma. , 2014, The international journal of biochemistry & cell biology.

[30]  Z. Younossi,et al.  Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease , 2016, BMJ open gastroenterology.

[31]  A. López de Munain,et al.  Six Serum miRNAs Fail to Validate as Myotonic Dystrophy Type 1 Biomarkers , 2016, PloS one.

[32]  E. Tapper,et al.  Use of Liver Imaging and Biopsy in Clinical Practice , 2017, The New England journal of medicine.

[33]  A. Pulvirenti,et al.  Intracellular and extracellular miRNome deregulation in cellular models of NAFLD or NASH: Clinical implications. , 2016, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[34]  Munis Dundar,et al.  Circulating microRNAs in patients with non-alcoholic fatty liver disease. , 2014, World journal of hepatology.

[35]  D. Crabb,et al.  Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases , 2020, Hepatology.

[36]  Mingshi Yang,et al.  miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR. , 2015, International journal of molecular medicine.

[37]  Hiroya Yamada,et al.  Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[38]  Laura Beretta,et al.  Circulating MicroRNAs in Patients with Chronic Hepatitis C and Non-Alcoholic Fatty Liver Disease , 2011, PloS one.

[39]  I. Pogribny,et al.  MicroRNAs as biomarkers for clinical studies , 2018, Experimental biology and medicine.

[40]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[41]  Z. Wang,et al.  Combination of let-7d-5p, miR-26a-5p, and miR-15a-5p is suitable normalizer for studying microRNA expression in skin tissue of Liaoning cashmere goat during hair follicle cycle. , 2016 .

[42]  Youwen Tan,et al.  A Pilot Study of Serum MicroRNAs Panel as Potential Biomarkers for Diagnosis of Nonalcoholic Fatty Liver Disease , 2014, PloS one.

[43]  L. Bolondi,et al.  Significance of serum and hepatic microRNA‐122 levels in patients with non‐alcoholic fatty liver disease , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[44]  David Campbell,et al.  The update , 2018, Co-Constructing Therapeutic Conversations.

[45]  J. Qu,et al.  Identification of reference genes for circulating microRNA analysis in colorectal cancer , 2016, Scientific Reports.

[46]  Michael Q. Zhang,et al.  Recurrently deregulated lncRNAs in hepatocellular carcinoma , 2017, Nature Communications.

[47]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[48]  S. Subramaniam,et al.  Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study , 2015, Gut.